{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T14:10:53Z","timestamp":1763388653959,"version":"3.45.0"},"reference-count":27,"publisher":"S.C. JURNALUL PENTRU MEDICINA SI VIATA S.R.L","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.25122\/jml-2025-0050","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T14:05:33Z","timestamp":1763388333000},"page":"869-877","source":"Crossref","is-referenced-by-count":0,"title":["Management outcomes of prolactinoma: a retrospective study from Southern Iraq"],"prefix":"10.25122","volume":"18","author":[{"given":"Haider Ayad","family":"Alidrisi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Medicine, Faiha Specialized Diabetes, Endocrine, and Metabolism Center, College of Medicine, University of Basrah, Basrah, Iraq","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasan Falah","family":"Alobaidy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Al-Hassan Metabolism, Endocrine, and Diabetes Center, Karbala, Iraq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khulood Abed","family":"Reman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Medicine, Faiha Specialized Diabetes, Endocrine, and Metabolism Center, College of Medicine, University of Basrah, Basrah, Iraq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qusay Baqer","family":"Alzujajy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Al-Hassan Metabolism, Endocrine, and Diabetes Center, Karbala, Iraq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim Hani","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Medicine, Faiha Specialized Diabetes, Endocrine, and Metabolism Center, College of Medicine, University of Basrah, Basrah, Iraq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abbas Ali","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Medicine, Faiha Specialized Diabetes, Endocrine, and Metabolism Center, College of Medicine, University of Basrah, Basrah, Iraq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10755","reference":[{"issue":"3","key":"ref1","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1007\/s12020-020-02497-w","article-title":"Hypeprolactinemia: still an insidious diagnosis","volume":"72","author":"Aliberti L, Gagliardi I, Dorizzi RM, Pizzicotti S, Bondanelli M, Zatelli MC","year":"2021","unstructured":"1. Aliberti L, Gagliardi I, Dorizzi RM, Pizzicotti S, Bondanelli M, Zatelli MC, Hypeprolactinemia: still an insidious diagnosis, Endocrine, 2021;72(3):928-931","journal-title":"Endocrine"},{"issue":"2","key":"ref2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA","year":"2011","unstructured":"2. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab, 2011;96(2):273-88","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"ref3","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jama.2016.19699","article-title":"Diagnosis and Treatment of Pituitary Adenomas: A Review","volume":"317","author":"Molitch ME","year":"2017","unstructured":"3. Molitch ME, Diagnosis and Treatment of Pituitary Adenomas: A Review, JAMA, 2017;317(5):516-524","journal-title":"JAMA"},{"issue":"5","key":"ref4","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/BF03346388","article-title":"Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients","volume":"31","author":"Vilar L, Freitas MC, Naves LA, Casulari LA, Azevedo M, Montenegro R","year":"2008","unstructured":"4. Vilar L, Freitas MC, Naves LA, Casulari LA, Azevedo M, Montenegro R, Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients, J Endocrinol Invest, 2008;31(5):436-44","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"ref5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11102-019-01024-z","article-title":"Biochemical diagnosis in prolactinomas: some caveats","volume":"23","author":"Petersenn S","year":"2020","unstructured":"5. Petersenn S, Biochemical diagnosis in prolactinomas: some caveats, Pituitary, 2020;23(1):9-15","journal-title":"Pituitary"},{"issue":"3","key":"ref6","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1530\/eje.0.1480325","article-title":"Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia","volume":"148","author":"Colao A, Sarno AD, Cappabianca P, Briganti F, Pivonello R, Somma CD","year":"2003","unstructured":"6. Colao A, Sarno AD, Cappabianca P, Briganti F, Pivonello R, Somma CD, Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia, Eur J Endocrinol, 2003;148(3):325-31","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"ref7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11102-019-01009-y","article-title":"Prolactinomas in males: any differences?","volume":"23","author":"Duskin-Bitan H, Shimon I","year":"2020","unstructured":"7. Duskin-Bitan H, Shimon I, Prolactinomas in males: any differences?, Pituitary, 2020;23(1):52-57","journal-title":"Pituitary"},{"issue":"3","key":"ref8","doi-asserted-by":"publisher","first-page":"dgz076","DOI":"10.1210\/clinem\/dgz076","article-title":"Impulse Control Disorders in Dopamine Agonist-Treated Hyperprolactinemia: Prevalence and Risk Factors","volume":"105","author":"De Sousa SMC, Baranoff J, Rushworth RL, Butler J, Sorbello J, Vorster J","year":"2020","unstructured":"8. De Sousa SMC, Baranoff J, Rushworth RL, Butler J, Sorbello J, Vorster J, Impulse Control Disorders in Dopamine Agonist-Treated Hyperprolactinemia: Prevalence and Risk Factors, J Clin Endocrinol Metab, 2020;105(3):dgz076","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"ref9","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1210\/clinem\/dgz144","article-title":"Surgery as a Viable Alternative First-Line Treatment for Prolactinoma Patients. A Systematic Review and Meta-Analysis","volume":"105","author":"Zamanipoor Najafabadi AH, Zandbergen IM, de Vries F, Broersen LHA, van den Akker-van Marle ME, Pereira AM","year":"2020","unstructured":"9. Zamanipoor Najafabadi AH, Zandbergen IM, de Vries F, Broersen LHA, van den Akker-van Marle ME, Pereira AM, Surgery as a Viable Alternative First-Line Treatment for Prolactinoma Patients. A Systematic Review and Meta-Analysis, J Clin Endocrinol Metab, 2020;105(3):e32-41","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"ref10","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/cen.12242","article-title":"Giant prolactinomas: the therapeutic approach","volume":"79","author":"Moraes AB, Silva CM, Vieira Neto L, Gadelha MR","year":"2013","unstructured":"10. Moraes AB, Silva CM, Vieira Neto L, Gadelha MR, Giant prolactinomas: the therapeutic approach, Clin Endocrinol (Oxf), 2013;79(4):447-56","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"ref11","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ando.2015.04.002","article-title":"Management of clinically non-functioning pituitary adenoma","volume":"76","author":"Chanson P, Raverot G, Castinetti F, Cortet-Rudelli C, Galland F, Salenave S, French Endocrinology Society non-functioning pituitary adenoma work-group","year":"2015","unstructured":"11. Chanson P, Raverot G, Castinetti F, Cortet-Rudelli C, Galland F, Salenave S, French Endocrinology Society non-functioning pituitary adenoma work-group, Management of clinically non-functioning pituitary adenoma, Ann Endocrinol (Paris), 2015;76(3):239-47","journal-title":"Ann Endocrinol (Paris)"},{"issue":"2","key":"ref12","doi-asserted-by":"publisher","first-page":"101290","DOI":"10.1016\/j.beem.2019.101290","article-title":"The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new","volume":"33","author":"Chanson P, Maiter D","year":"2019","unstructured":"12. Chanson P, Maiter D, The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new, Best Pract Res Clin Endocrinol Metab, 2019;33(2):101290","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"430","DOI":"10.12688\/f1000research.13632.2","article-title":"Spectrum of Pituitary disorders: A retrospective study from Basrah, Iraq","volume":"7","author":"Mansour AA, Alhamza AHA, Almomin AMSA, Zaboon IA, Alibrahim NTY, Hussein RN, Kadhim MB, Alidrisi HAY, Nwayyir HA, Mohammed AG, Al-Waeli DK, Hussein IH","year":"2018","unstructured":"13. Mansour AA, Alhamza AHA, Almomin AMSA, Zaboon IA, Alibrahim NTY, Hussein RN, Kadhim MB, Alidrisi HAY, Nwayyir HA, Mohammed AG, Al-Waeli DK, Hussein IH, Spectrum of Pituitary disorders: A retrospective study from Basrah, Iraq, F1000Res, 2018;7430","journal-title":"F1000Res"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.clineuro.2018.11.024","article-title":"Fertility after transsphenoidal surgery in patients with prolactinomas: A meta-analysis","volume":"176","author":"Lamba N, Noormohamed N, Simjian T, Alsheikh MY, Jamal A, Doucette J","year":"2019","unstructured":"14. Lamba N, Noormohamed N, Simjian T, Alsheikh MY, Jamal A, Doucette J, Fertility after transsphenoidal surgery in patients with prolactinomas: A meta-analysis, Clin Neurol Neurosurg, 2019;17653-60","journal-title":"Clin Neurol Neurosurg"},{"issue":"3","key":"ref15","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3109\/07435800.2015.1135444","article-title":"Obesity and hypercholesterolemia in patients with prolactinomas: Could DHEA-S and growth hormone be the missing link?","volume":"41","author":"Peri\u0107 B, Kruljac I, \u0160undali\u0107 S, Pe\u0107ina HI, Jovi\u0107 A, \u0160tefanovi\u0107 M","year":"2016","unstructured":"15. Peri\u0107 B, Kruljac I, \u0160undali\u0107 S, Pe\u0107ina HI, Jovi\u0107 A, \u0160tefanovi\u0107 M, Obesity and hypercholesterolemia in patients with prolactinomas: Could DHEA-S and growth hormone be the missing link?, Endocr Res, 2016;41(3):200-6","journal-title":"Endocr Res"},{"issue":"3","key":"ref16","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.ecl.2020.05.006","article-title":"The Role of Dopamine Agonists in Pituitary Adenomas","volume":"49","author":"Giraldi EA, Ioachimescu AG","year":"2020","unstructured":"16. Giraldi EA, Ioachimescu AG, The Role of Dopamine Agonists in Pituitary Adenomas, Endocrinol Metab Clin North Am, 2020;49(3):453-474","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"10","key":"ref17","doi-asserted-by":"publisher","first-page":"e29822","DOI":"10.7759\/cureus.29822","article-title":"Prolactinoma: Clinical Characteristics, Management and Outcome","volume":"14","author":"Irfan H, Shafiq W, Siddiqi AI, Ashfaq S, Attaullah S, Munir Alvi A","year":"2022","unstructured":"17. Irfan H, Shafiq W, Siddiqi AI, Ashfaq S, Attaullah S, Munir Alvi A, Prolactinoma: Clinical Characteristics, Management and Outcome, Cureus, 2022;14(10):e29822","journal-title":"Cureus"},{"issue":"5","key":"ref18","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1210\/er.2005-9998","article-title":"Advances in the treatment of prolactinomas","volume":"27","author":"Gillam MP, Molitch ME, Lombardi G, Colao A","year":"2006","unstructured":"18. Gillam MP, Molitch ME, Lombardi G, Colao A, Advances in the treatment of prolactinomas, Endocr Rev, 2006;27(5):485-534","journal-title":"Endocr Rev"},{"issue":"6","key":"ref19","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/qjmed\/hcs240","article-title":"Macroprolactinoma: a diagnostic and therapeutic update","volume":"106","author":"Iglesias P, D\u00edez JJ","year":"2013","unstructured":"19. Iglesias P, D\u00edez JJ, Macroprolactinoma: a diagnostic and therapeutic update, QJM, 2013;106(6):495-504","journal-title":"QJM"},{"issue":"7","key":"ref20","doi-asserted-by":"publisher","first-page":"998","DOI":"10.25122\/jml-2022-0196","article-title":"Comparing MRI volume measurement techniques for pituitary macroadenoma: Investigating volume reduction and its relationship with biochemical control","volume":"16","author":"Hussein IH, Mansour AA, Jameel NA","year":"2023","unstructured":"20. Hussein IH, Mansour AA, Jameel NA, Comparing MRI volume measurement techniques for pituitary macroadenoma: Investigating volume reduction and its relationship with biochemical control, J Med Life, 2023;16(7):998-1006","journal-title":"J Med Life"},{"issue":"7","key":"ref21","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1210\/jcem.84.7.5810","article-title":"Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients","volume":"84","author":"Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B","year":"1999","unstructured":"21. Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients, J Clin Endocrinol Metab, 1999;84(7):2518-22","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"ref22","doi-asserted-by":"publisher","first-page":"5256","DOI":"10.1210\/jcem.86.11.8054","article-title":"Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy","volume":"86","author":"Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R","year":"2001","unstructured":"22. Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy, J Clin Endocrinol Metab, 2001;86(11):5256-61","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"ref23","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1210\/jcem.85.6.6657","article-title":"Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients","volume":"85","author":"Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R","year":"2000","unstructured":"23. Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients, J Clin Endocrinol Metab, 2000;85(6):2247-52","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"ref24","doi-asserted-by":"publisher","first-page":"e615","DOI":"10.1210\/clinem\/dgaa744","article-title":"Biochemical Remission after Cabergoline Withdrawal in Hyperprolactinemic Patients with Visible Remnant Pituitary Adenoma","volume":"106","author":"Kim K, Park YW, Kim D, Ahn SS, Moon JH, Kim EH","year":"2021","unstructured":"24. Kim K, Park YW, Kim D, Ahn SS, Moon JH, Kim EH, Biochemical Remission after Cabergoline Withdrawal in Hyperprolactinemic Patients with Visible Remnant Pituitary Adenoma, J Clin Endocrinol Metab, 2021;106(2):e615-e624","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"ref25","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.4158\/EP15804.OR","article-title":"Short-Term Decline in Prolactin Concentrations can Predict Future Prolactin Normalization, Tumor Shrinkage, and Time to Remission in Men with Macroprolactinomas","volume":"21","author":"Tirosh A, Benbassat C, Shimon I","year":"2015","unstructured":"25. Tirosh A, Benbassat C, Shimon I, Short-Term Decline in Prolactin Concentrations can Predict Future Prolactin Normalization, Tumor Shrinkage, and Time to Remission in Men with Macroprolactinomas, Endocr Pract, 2015;21(11):1240-7","journal-title":"Endocr Pract"},{"issue":"3","key":"ref26","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3803\/EnM.2014.29.3.280","article-title":"Early prediction of long-term response to cabergoline in patients with macroprolactinomas","volume":"29","author":"Lee Y, Ku CR, Kim EH, Hong JW, Lee EJ, Kim SH","year":"2014","unstructured":"26. Lee Y, Ku CR, Kim EH, Hong JW, Lee EJ, Kim SH, Early prediction of long-term response to cabergoline in patients with macroprolactinomas, Endocrinol Metab (Seoul), 2014;29(3):280-92","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"4","key":"ref27","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1530\/EJE-21-0561","article-title":"Shrinkage by the third month predicts long-term response of macroprolactinoma after cabergoline","volume":"185","author":"Biagetti B, Sarria-Estrada S, Ng-Wong YK, Martinez-Saez E, Caster\u00e0s A, Cordero Asanza E","year":"2021","unstructured":"27. Biagetti B, Sarria-Estrada S, Ng-Wong YK, Martinez-Saez E, Caster\u00e0s A, Cordero Asanza E, Shrinkage by the third month predicts long-term response of macroprolactinoma after cabergoline, Eur J Endocrinol, 2021;185(4):587-595","journal-title":"Eur J Endocrinol"}],"container-title":["Journal of Medicine and Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/medandlife.org\/all-issues\/2025\/issue-9-2025\/original-article-issue-9-2025\/management-outcomes-of-prolactinoma-a-retrospective-study-from-southern-iraq\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T14:05:47Z","timestamp":1763388347000},"score":1,"resource":{"primary":{"URL":"https:\/\/medandlife.org\/all-issues\/2025\/issue-9-2025\/original-article-issue-9-2025\/management-outcomes-of-prolactinoma-a-retrospective-study-from-southern-iraq\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["JMedLife-18-869"],"URL":"https:\/\/doi.org\/10.25122\/jml-2025-0050","relation":{},"ISSN":["1844-3117"],"issn-type":[{"value":"1844-3117","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]}}}